Search

Natalie Fursov

from Harleysville, PA
Age ~54
Get Report
Also known as:
Natalia Fursov, Natalia Zakharova, Natalia Zakharov, Natalya Zakharova, Natalya Zakhardva, Manzano Florentin, Natalia H, Natalie U
Phone and address:
280 Manor Rd, Harleysville, PA 19438
(215) 256-1406
Related to:
Cynthia Mack Smeltzer, 57Craig Eberhardt, 74Jeffrey DawsonJoseph DawsonGail Everhardt, 66
Connected to:
Galina G Fursova, 68Paul A Fursov, 33Philip B Furspan, 70Alan N Furst, 74Albert J Furst, 83Angelyn S Furst, 76Bernard F Furst, 98Chad A Furst, 36Dan M Furst, 65Dylan J Furst, 32

Natalie Fursov Phones & Addresses

  • 280 Manor Rd, Harleysville, PA 19438 (215) 256-1406
  • 288 Manor Rd, Harleysville, PA 19438 (215) 256-1406
  • Lower Salford, PA
  • Norristown, PA
  • New York, NY
  • Piscataway, NJ
  • Montgomery, PA

Publications

Us Patents

Macaca Fascicularis St2L

View page
US Patent:
20100247442, Sep 30, 2010
Filed:
Mar 31, 2009
Appl. No.:
12/415095
Inventors:
Adam Cotty - Radnor PA, US
Natalie Fursov - Radnor PA, US
Michael Naso - Radnor PA, US
International Classification:
A61K 49/00
C07H 21/00
C12N 15/63
C12N 5/00
C07K 14/00
C12P 21/00
C07K 16/00
G01N 33/53
C12Q 1/02
C12Q 1/68
US Classification:
424 92, 536 235, 4353201, 435325, 530350, 435 691, 5303879, 436501, 435 29, 435 6
Abstract:
Isolated polynucleotides encoding ST2L (Cyno ST2L), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

St2L Antagonists And Methods Of Use

View page
US Patent:
20130287777, Oct 31, 2013
Filed:
Mar 13, 2013
Appl. No.:
13/798226
Inventors:
Karen Duffy - Spring House PA, US
Natalie Fursov - Spring House PA, US
LeRoy Hall - Raritan NJ, US
Catherine Healy - Spring House PA, US
Roberta Lamb - Spring House PA, US
Jinquan Luo - Spring House PA, US
Ravi Malaviya - Spring House PA, US
Michael Naso - Spring House PA, US
Michael Pratta - Spring House PA, US
Mark Tornetta - Spring House PA, US
John Wheeler - Spring House PA, US
Assignee:
JANSSEN BIOTECH, INC. - Horsham PA
International Classification:
C07K 16/28
US Classification:
4241361, 4241331, 4241391
Abstract:
The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

St2L Antagonists And Methods Of Use

View page
US Patent:
20130336980, Dec 19, 2013
Filed:
Mar 13, 2013
Appl. No.:
13/798204
Inventors:
Natalie Fursov - Spring House PA, US
LeRoy Hall - Raritan NJ, US
Catherine Healy - Spring House PA, US
Roberta Lamb - Spring House PA, US
Jinquan Luo - Spring House PA, US
Ravi Malaviya - Spring House PA, US
Michael Naso - Spring House PA, US
Michael Pratta - Mulica Hill NJ, US
Mark Tornetta - Spring House PA, US
John Wheeler - Spring House PA, US
Assignee:
JANSSEN BIOTECH, INC. - Horsham PA
International Classification:
C07K 16/28
US Classification:
4241361, 5303879, 536 2353, 4353201, 435 696, 4241391, 4241721, 435419, 4352523, 435331
Abstract:
The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

Human Anti-Cd27 Antibodies

View page
US Patent:
20200277393, Sep 3, 2020
Filed:
May 19, 2020
Appl. No.:
16/878209
Inventors:
- Horsham PA, US
Johan Fransson - Toronto, CA
Natalie Fursov - Harleysville PA, US
Damon Hamel - San Diego CA, US
Thomas Malia - Philadelphia PA, US
Galina Obmolova - Phoenixville PA, US
Tatiana Ort - Plymouth Meeting PA, US
Michael Rycyzyn - Berwyn PA, US
Michael Scully - Medford NJ, US
Raymond Sweet - Bryn Mawr PA, US
Alexey Teplyakov - Phoenixville PA, US
John Wheeler - Devon PA, US
Juan Carlos Almagro - Brookline MA, US
International Classification:
C07K 16/28
Abstract:
Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Methods Of Inhibiting Activity Using Anti-Cd27 Antibodies

View page
US Patent:
20190248910, Aug 15, 2019
Filed:
Apr 12, 2019
Appl. No.:
16/382645
Inventors:
- Horsham PA, US
Johan Fransson - Toronto, CA
Natalie Fursov - Harleysville PA, US
Damon Hamel - San Diego CA, US
Thomas Malia - Philadelphia PA, US
Galina Obmolova - Phoenixville PA, US
Tatiana Ort - Plymouth Meeting PA, US
Michael Rycyzyn - Berwyn PA, US
Michael Scully - Medford NJ, US
Raymond Sweet - Bryn Mawr PA, US
Alexey Teplyakov - Phoenixville PA, US
John Wheeler - Devon PA, US
Juan Carlos Almagro - Brookline MA, US
International Classification:
C07K 16/28
Abstract:
Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Methods Of Inhibiting Activity Using Anti-Cd27 Antibodies

View page
US Patent:
20170320957, Nov 9, 2017
Filed:
May 16, 2017
Appl. No.:
15/596609
Inventors:
- Horsham PA, US
Johan Fransson - Toronto, CA
Natalie Fursov - Harleysville PA, US
Damon Hamel - San Diego CA, US
Thomas Malia - Philadelphia PA, US
Galina Obmolova - Phoenixville PA, US
Tatiana Ort - Plymouth Meeting PA, US
Michael Rycyzyn - Berwyn PA, US
Michael Scully - Medford NJ, US
Raymond Sweet - Bryn Mawr PA, US
Alexey Teplyakov - Phoenixville PA, US
John Wheeler - Devon PA, US
Juan Carlos Almagro - Brookline MA, US
International Classification:
C07K 16/28
C07K 16/28
A61K 39/00
Abstract:
Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

St2L Antagonists And Methods Of Use

View page
US Patent:
20170066831, Mar 9, 2017
Filed:
Nov 12, 2015
Appl. No.:
14/939624
Inventors:
- Horsham PA, US
Natalie Fursov - Harleysville PA, US
LeRoy Hall - Raritan NJ, US
Catherine Healy - Spring House PA, US
Roberta Lamb - Wynnewood PA, US
Jinquan Luo - Malvern PA, US
Ravi Malaviya - Spring House PA, US
Michael Naso - Spring House PA, US
Michael Pratta - Mulica Hill NJ, US
Mark Tornetta - Collegeville PA, US
John Wheeler - Devon PA, US
Sheng-Jiun Wu - Broomall PA, US
International Classification:
C07K 16/28
Abstract:
The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Control profile
Natalie Fursov from Harleysville, PA, age ~54 Get Report